LAB vs MET · rev $174.4M vs P/E 13, $52.16B cap
Standard Biotools Inc (LAB) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
MET does not have a complete income-statement cache yet.
LAB currently screens at market cap $317.1M. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the LAB and MET stock pages for the full models.
Not investment advice.